| Field | Specification |
|---|---|
| Mfr No | |
| Product Type | |
| Shipping | |
| Species | |
| Storage |
Scientific Background
The development of CAR-T cells is a complex process that requires multiple steps in the workflow including I) screening and sequencing of mAbs that are specific to the cancer antigens; II) engineering and validation of scFv and scFv-CAR of different varieties for their specificities and activities; III) production of high titer lentivirus for CAR constructs; IV) isolation, activation and expansion of primary T cells from healthy donors or patients that exhibit a specific cellular phenotype; V) transduction of activated T cells with CAR-encoding lentivirus; VI) validation of engineered CAR-T cells through FACS and functional analysis. BPS Bioscience has developed a series of CAR-T products, including lentiviruses, reporter cell lines and fully validated functional CAR-T cells for a variety of targets such as CD19 and BCMA. In this product, anti-CD19 CAR negative control and NFAT-luciferase reporter are co-transfected into a Jurkat cell line, where the anti-CD19 scFv binds to CD19, however, it does not induce the activation of CAR and luciferase reporter through NFAT as the intracellular activation motifs are missing. Anti-CD19 scFv linked to the CD28 transmembrane region was cloned into a lentivector, and packaged using a safe, replication incompetent, and VSV-G pseudotyped lentiviral packaging system, in which the gene of anti-CD19 CAR negative control is driven by an EF-1α promotor. Anti-CD19 CAR negative control Jurkat/NFAT reporter cell line was generated by the transduction of anti-CD19 CAR negative control lentivirus into an NFAT-luciferase reporter Jurkat cell line. In these cells, the luciferase reporter should not be activated upon co-culture with CD19/CHO target cells (BPS Bioscience #79561). Anti-CD19 CAR/NFAT-luciferase reporter Jurkat cell line (BPS Bioscience, #79853) is a great system for primary screening of anti-CD19 CAR and predicting its mechanism of action before testing on patient-derived primary T cells. The same anti-CD19 CAR lentivirus (BPS Bioscience, #79851) was also used to transduce primary T cells to make primary anti-CD19 CAR-T cells, which showed IFN-γ production and cytotoxic killing of CD19+ tumor cells in co-culture experiments, indicating that there is a good correlation between the reporter activity in CAR reporter Jurkat cell line and functional activation of primary CAR-T cells when co-cultured with target cells.
Product Description
CAR-TAnti-CD19 CAR negative control/NFAT-luciferase reporter Jurkat cell line is a double stable cell line expressing anti-CD19 CAR negative control and NFAT-luciferase reporter. The anti-CD19 CAR negative control consists of anti-CD19 scFv linked to the CD28 transmembrane motif without any intracellular signaling domains. The reporter cell line has been validated for anti- CD19 expression by FACS, while the stimulation by target cells including CD19/CHO recombinant cell line has not activated the luciferase reporter gene in this cell line. The cell line can be used for the negative control of anti-CD19 CAR/Jurkat-NFAT cell line (BPS Bioscience, #79853).
Product Specifications
| Host Cell Line | Jurkat (clone E6-1) |
|---|---|
| Host Species | Human t lymphoblast, suspension |
| Transfection Method | Lentivirus, no catalog number, |
| Supplied As | Each vial contains 2 x 10^6 cells in 1 ml of 10% DMSO and 90% FBS |
| Harmonized Tariff Code | 3002-5900 |
Quality Control & Validation
✓ Mycoplasma-TestedThe cell line has been screened using Lonza MycoAlert Mycoplasma Detection kit (Lonza, #LT07-318) to confirm the absence of Mycoplasma species.
Safety & Handling
⚠ Avoid freeze/thaw cycles.
Regulatory Information
License Disclosure
Related Products
Related Products: Cat. #60690, 60184, 79796, 79784, 79853
Required Accessories: Cat. #60184,79784,79796,60690
This product is engineered on a Jurkat (clone E6-1) background (Human origin). The Jurkat (clone E6-1) host was selected for its compatibility with stable transfection and the target pathway or assay type. Consult the product datasheet for passage number guidance and recommended culture media.
This product is classified as BSL-1. Standard microbiological practices (gloves, lab coat, eye protection) are sufficient. No specialized containment facility is required beyond a clean bench. Consult your institutional IBC for GMO registration requirements.
Yes. The cell line has been screened using Lonza MycoAlert Mycoplasma Detection kit (Lonza, #LT07-318) to confirm the absence of Mycoplasma species. We recommend that you independently confirm mycoplasma-negative status after receipt and periodically during routine culture using a validated detection kit.
Store this product at Liquid Nitrogen. Specifically: Immediately upon receipt, store in liquid nitrogen. Transfer cells from dry-ice shipping to the recommended storage immediately upon receipt. Avoid repeated freeze-thaw cycles, which reduce viability and may alter expression characteristics.
Yes, a license is required (Yes). Purchase of this cell line grants a time-limited research-use license for use in your immediate laboratory only. This license does not permit redistribution, sub-licensing, transfer to other institutions, or commercial use. Refer to the License Disclosure section on this page or contact BPS Bioscience for details regarding modifications or commercial licensing.
This stable cell line was generated using Lentivirus, no catalog number, for transgene delivery into the parental host. The stably integrated cells were selected using the appropriate resistance marker and verified for expression prior to cryopreservation.
Can't find the cell line you need—or require a custom engineered model for your study? We offer end-to-end support for diverse research needs, including:
- Cell line sourcing and selection (species, tissue, and disease model matching)
- Stable cell line engineering (overexpression, knockdown, knockout via CRISPR/Cas9, shRNA, sgRNA)
- Reporter gene integration (GFP, RFP, luciferase, fluorescent/bioluminescent constructs)
- Genome editing and knockin (point mutations, tagged endogenous proteins, conditional alleles)
- Inducible expression systems (Tet-On/Off and regulatable constructs)
- Drug resistance marker selection (puromycin, G418, hygromycin, and others)
- Custom growth and media optimisation for specific assay requirements
- Scale-up production for high-throughput screening campaigns
- Authentication and QC services (STR profiling, mycoplasma testing, viability assessment)
Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.Wang et al. J Hematol Oncol. 2019 Jun 11;12(1):59-78.
- Chimeric antigen receptor T cell therapy for multiple myeloma. Hasegawa et al. Inflamm Regen. 2019 Jun 4;39:10-14.
- Novel targets for the treatment of relapsing multiple myeloma. Giuliani et al. Expert Rev Hematol. 2019 Jun 3:1-16.
- Anti-CD19 antibodies in the future management of multiple myeloma. Gavriatopoulou et al. Expert Rev Anticancer Ther. 2019 Apr;19(4):319-326.
